Eton Pharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: Los Angeles CA United States (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2018
NCT03489941
First Marketed Drug
2019
phenylephrine (Prefrin)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ETON | Eton Pharmaceuticals, Inc. | ETON PHARMS

Active Ingredients

Marketed Drugs (5)

betaine (2022)

ephedrine (2021)

nitisinone (orfadin) (2023)

phenylephrine (Prefrin) (2019)

urea (2020)

Drugs in Phase 3 Trials (2)

em-100 (1 trial)

ketotifen (zaditor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2